Revolution Medicines FDA Approval Clears Rasonque

Revolution Medicines, Inc. (Nasdaq: RVMD) received FDA approval on Aug. 26, 2026, for RASONQUE (daraxonrasib), an oral therapy for adults with previously treated metastatic pancreatic adenocarcinoma. The approval enables immediate U.S. availability and supports the company’s plans for broader registrational studies.

Clinical Trial Results Behind Approval

The FDA based its decision on RASolute 302, a global, randomized phase 3 trial comparing daraxonrasib with investigator-choice cytotoxic chemotherapy in 500 adults with previously treated metastatic pancreatic adenocarcinoma. The trial showed a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, with a hazard ratio for death of 0.40 (p<0.0001), indicating a 60% reduction in risk of death.

Secondary endpoints demonstrated higher tumor response and longer disease control. The objective response rate was 31.6% on daraxonrasib versus 11.2% with chemotherapy (p<0.0001). Among patients with RAS G12 mutations, median progression-free survival was 7.3 months compared with 3.5 months on chemotherapy (hazard ratio 0.45, p<0.001), with response rates near 33.2% versus 11.8%.

The FDA identified rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage as the most common side effects. Trial data showed lower rates of severe and serious treatment-related adverse events (TRAEs) with daraxonrasib than chemotherapy: grade 3 or higher TRAEs occurred in 43.6% versus 57.5%, serious TRAEs in 10.8% versus 18.7%, and treatment discontinuations due to toxicity were 1.2% versus 11.2%. One treatment-related death from pneumonitis occurred in the daraxonrasib arm. The European Society for Medical Oncology (ESMO) noted cutaneous toxicity, including scalp involvement, as a distinctive adverse-event pattern.

Regulatory Designations and Commercial Outlook

The FDA granted RASONQUE Breakthrough Therapy and Orphan Drug designations and reviewed the application under Priority Review. The agency approved the drug about 6.5 months before the user-fee deadline. Revolution Medicines submitted its new-drug application on July 22, 2025, using a national review voucher that shortened the review timeline.

The approved label covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The company emphasized that the indication applies with or without an identified RAS tumor mutation and does not require a companion diagnostic. RASONQUE is supplied as 300 mg once-daily oral tablets. Revolution Medicines plans additional registrational trials, including in metastatic RAS-mutant non-small-cell lung cancer.

By early August, more than 2,000 patients had received daraxonrasib under expanded access or compassionate-use programs, with plans to transition them to commercial coverage following approval.

The ESMO Express Update on Aug. 19, 2026, incorporated daraxonrasib into its pancreatic cancer treatment algorithm, recommending monotherapy after chemotherapy failure for patients with RAS G12-mutated metastatic disease and good performance status (ECOG 0–1). The guideline assigned this recommendation a high evidence strength and a grade A rating.

Together, the broad label, the company’s launch readiness, and the existing expanded-access patient pool position Revolution Medicines to convert trial results into near-term U.S. prescriptions.

FDA Statement on RASONQUE

“Rasonque, a tablet taken once daily, targets multiple forms of a protein called RAS, a key driver of tumor growth in most patients with pancreatic adenocarcinoma,” the FDA said in its approval announcement.